MedTrace Logo

A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC

NCT00144989 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 281

Last updated 2016-09-22

No results posted yet for this study

Summary

To evaluate the role of 3 cycles of irinotecan and cisplatin for patients with limited-stage small-cell lung cancer who received one course of etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic irradiation.

Conditions

  • Small-Cell-Lung Cancer

Interventions

DRUG

Etoposide and cisplatin after chemoradiotherapy

Etoposide and cisplatin after chemoradiotherapy

DRUG

Irinotecan and cisplatin after chemoradiotherapy

Irinotecan and cisplatin after chemoradiotherapy

Sponsors & Collaborators

  • Ministry of Health, Labour and Welfare, Japan

    collaborator OTHER_GOV

  • Haruhiko Fukuda

    lead OTHER

Principal Investigators

  • Yutaka Nishiwaki, MD · National Cancer Center Hospital East

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00144989 on ClinicalTrials.gov